-
-
-
-
-
-
-
Stoke, Biogen share 4-year data on zorevunersen for Dravet syndrome
-
-
-
-
-
-
-
Eisai, Biogen launch subcutaneous Leqembi autoinjector in the U.S.
-
-
-
-
-
-
-
Oppenheimer Reiterates Outperform Rating on Biogen (BIIB)
-
-
-
-
-
-
-
Truist upgrades Biogen to Buy on Alzheimer's, pipeline optimism ahead of key data
-
-
-
-
-
-
-
Needham Upgrades Biogen (BIIB) to Buy
-
-
-
-
-
-
-
Jefferies: 'we think BIIB stock could climb higher on the resiliency of the commercial franchise'
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Biogen (BIIB)
-
481,308 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


